We address an underserved serious postmenopausal condition, vulvovaginal atrophy (VVA), which affects over 32 million women in the U.S.
We are developing a unique, local, easily administered, non-estrogen product, especially attractive to breast cancer survivors.
We are committed to addressing the unmet women’s health needs and delivering solutions to postmenopausal women worldwide.